[1] |
严骏,翁方中,戴伟,等.CYP2C19基因多态性与缺血性脑卒中发病及预后的相关性[J].中国老年学杂志,2019,39(21):5187-5191.
|
[2] |
宁来轩.氯吡格雷联合阿司匹林治疗短暂性脑缺血发作的疗效观察[J].中国实用神经疾病杂志,2019,22(12):1358-1363.
|
[3] |
利程,陈文礼,李亚男,等.珠中江地区脑卒中患者CYP2C19基因多态性差异性分布[J].今日药学,2019,29(9):626-628,632.
|
[4] |
李笑笑,吕佳宁,范薇.CYP2C19基因多态性对氯吡格雷药效的影响[J].中国临床神经科学,2016,24(2):225-232.
|
[5] |
Bozzi LM, MitcheliI BD, Lewis JP,et al. The pharmacogenomics of anti-platelet intervention(PAPI)study:variation in platelet response toclopidogrel and aspirin[J].Curr Vasc Pharmacol,2016,14(1):116-124.
|
[6] |
Singh M, Thapa B, Arora R.Clopidogrel pharmacogenetics and its clinical implications[J].Am J Ther,2010,17(3):e66-e73.
|
[7] |
Lee JH, Basith S, Cui M, et al. In silico prediction of multiple-category classification model for cytochrome P450 inhibitors and non-inhibitors using machine-learning method.[J].SAR and QSAR Environ Res,2017,28(10):863-874.
|
[8] |
胡波.CYP2C19基因多态性对不同种族人群服用氯吡格雷疗效的影响[C]//中华医学会,中华医学会神经病学分会.中华医学会第十八次全国神经病学学术会议论文汇编(上),成都,2015:178-179.
|
[9] |
Dehbozorgi M, Behnam K, Iman H, et al. Prevalence of the CYP2C19*2 (681 G>;A),*3 (636 G>;A) and*17 (-806 C>;T) alleles among an Iranian population of different ethnicities[J].Mol Med Rep,2018,17(3):4195-4202.
|
[10] |
吴亚哲,陈伟伟.中国脑卒中流行概况[J].心脑血管病防治,2016,16(6):410-414.
|
[11] |
Antithrombotic Trialists′ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death,myocardial infarction,and stroke in high risk patients[J].BMJ,2002,324(7329):71-86.
|
[12] |
中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国缺血性脑卒中和短暂性脑缺血发作二级预防指南2014[J].中华神经科杂志,2015,48(4):258-273.
|
[13] |
孙新帅,冯青俐.氯吡格雷联合阿司匹林在TIA治疗和二级预防中的应用观察[J].中国实用神经疾病杂志,2009,12(10):30-32.
|
[14] |
Milionis HJ, Gerotziafas G, Kostapanos MS,et al.Clopidogrel vs.aspirin treatment on admission improves 5-year survival after a first-ever acute ischemic stroke.Data from the Athens Stroke Outcome Project[J].Arch Med Res,2011,42(6):443-450.
|
[15] |
任宏生,朱兴雷.氯吡格雷防治动脉粥样硬化缺血性疾病的研究进展[J].心血管病学进展,2006,27(3):274-281.
|
[16] |
Wang YJ, Liu M, Pu CQ.2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack[J].Int J Stroke,2017,12(3):302-320.
|
[17] |
Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack:a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J].Stroke,2014,45(7):2160-2236.
|
[18] |
何艳茹,党爱民.阿司匹林及氯吡格雷抵抗与基因多态性的研究进展[J].中华高血压杂志,2017,25(11):1084-1086.
|
[19] |
Uchiyama S.Clopidogrel resistance:identifying and overcoming a barrier to effective antiplatelet treatment[J].Cardiovas Ther,2011,29(6):e100-e111.
|
[20] |
Fefer P, Shlomi M.The genetic basis of platelet responsiveness to clopidogrel.A critical review of the literature[J].Thromb Haemost,2011,106(2):203-210.
|
[21] |
顾永丽,孙增先.阿司匹林抵抗与氯吡格雷抵抗的研究进展[J].中国医院药学杂志,2016,36(10):866-869.
|
[22] |
Brown SA, Pereira N. Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine[J].J Pers Med,2018,8(1):8.
|
[23] |
Zhong ZX, Hou JY, Li B, et al. Analysis of CYP2C19 genetic polymorphism in a Large Ethnic Hakka population in Southern China[J].Med Sci Monit,2017(23):6186-6192.
|
[24] |
莫延红,牛璇,张兆辉.CYP2C19基因多态性对临床常见药物代谢的影响[J].卒中与神经疾病,2019,26(4):499-507.
|
[25] |
张爱玲,胡欣,杨莉萍.亚洲健康人群CYP2C19基因型发生率的合并分析[J].中国循证医学杂志,2014,14(4):427-434.
|
[26] |
李静,郑伶利,陈静,等.基因突变检测在个体化用药中的研究进展[J].现代药物与临床,2018,33(4):1002-1008.
|
[27] |
庄献博,王未飞,单广振,等.青中年缺血性脑卒中患者血清抗心磷脂抗体免疫球蛋白G、白细胞介素-17、超敏C反应蛋白水平变化的意义[J/CD].中华诊断学电子杂志,2017,5(1):51-54.
|